Literature DB >> 17294720

[Establishment of an imatinib resistance cell line K562R and its resistant principia].

Huan-ling Zhu1, Ting Liu, Wen-tong Meng, Yong-qian Jia.   

Abstract

OBJECTIVE: To establish an imatinib resistance cell line and to study its resistant principia.
METHODS: K562 cells were cultured in imatinib at gradually increased concentrations to generate their resistance cell line. MTT assay, RT-PCR, flow cytometry and HPLC were used to clarify the possible mechanisms of the resistance.
RESULTS: (1) Imatinib resistance cell line K562R was successfully induced by continuous culture in the presence of gradually increasing doses of imatinib up to 5 micromol/L. K562R cells were maintained in the media containing 5 micromol/L imatinib. (2) Proliferation data showed that cell growth of K562R was not inhibited in 5 micromol/ L imatinib, whereas the parental sensitive cell was significantly inhibited by up to 2.0 micromol/L imatinib. (3) The IC50 of K562R was about 7.5 micromol/L which was ten times higher than that of the parental cell. (4) HPLC revealed that the intracellular imatinib concentration of K562R was strikingly lower than that of the parental cells (up to 27. 8-fold). By flow cytometry, P-gp was not detected on K562R cell, indicating that low intracellular imatinib concentration may not be due to P-gp mediated efflux. (5) Sequence analysis of the 374 bp ABL kinase domain showed no mutation in K562R cell.
CONCLUSION: An imatinib resistance cell line K562R has been successfully established. Low intracellular imatinib concentration is a key link in the chain of cell resistance.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17294720

Source DB:  PubMed          Journal:  Sichuan Da Xue Xue Bao Yi Xue Ban        ISSN: 1672-173X


  4 in total

1.  The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification.

Authors:  Dachuan Zeng; Miao Gao; Renren Zheng; Run Qin; Wei He; Suotian Liu; Wei Wei; Zhenglan Huang
Journal:  Exp Hematol Oncol       Date:  2022-05-27

2.  Wogonin reversed resistant human myelogenous leukemia cells via inhibiting Nrf2 signaling by Stat3/NF-κB inactivation.

Authors:  Xuefen Xu; Xiaobo Zhang; Yi Zhang; Lin Yang; Yicheng Liu; Shaoliang Huang; Lu Lu; Lingyi Kong; Zhiyu Li; Qinglong Guo; Li Zhao
Journal:  Sci Rep       Date:  2017-02-02       Impact factor: 4.379

3.  Induction of apoptosis in imatinib sensitive and resistant chronic myeloid leukemia cells by efficient disruption of bcr-abl oncogene with zinc finger nucleases.

Authors:  Ningshu Huang; Zhenglan Huang; Miao Gao; Zhenhong Luo; Fangzhu Zhou; Lin Liu; Qing Xiao; Xin Wang; Wenli Feng
Journal:  J Exp Clin Cancer Res       Date:  2018-03-20

4.  Establishment of a GIST-T1 gastrointestinal stromal tumour cell line resistant to imatinib mesylate.

Authors:  Yongjian Zhou; Jiabi Chen; Xiaoyuan Weng; Guosheng Lin; Zicheng Huang; Hanli Shui
Journal:  Oncol Lett       Date:  2018-03-16       Impact factor: 2.967

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.